- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of October 2
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of October 2.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 2.
Number 5: Medicines for Europe has released a new report, prepared by the Economist Intelligence Unit, that attempts to address the problem of medicines shortages in Europe.
Number 4: FDA Commissioner, Dr Scott Gottlieb, announced 2 new initiatives this week. One is aimed at increasing competition for complex generics, and the other streamlines the process for patients to receive investigational drugs for compassionate use.
Number 3: In a new report on drug spending, pharmacy benefit manager Express Scripts says that a group comprising less than 1% of US patients accounts for more than 20% of total pharmacy spending.
Number 2: Allergan is being sued by fellow Irish drug maker, Shire, over its embattled dry eye drug, Restasis.
Number 1: A newly published case report suggests that biosimilar infliximab could present a new treatment option for patients with HIV who develop mycobacterial immune reconstitution inflammatory syndrome.
Finally, last week, our newsletter asked for your input on how suffixes to biosimilars’ names should be addressed. To view results of our poll, visit The Center for Biosimilars® on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars
September 9th 2024Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes for reporting modifications, comparability assessments, and the potential for biosimilars to introduce new indications or formulation changes, which could significantly impact their market competitiveness and accessibility.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
